Ian Purvis

Mr. Ian Purvis

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2017
Verified
Journal Article
Closed access
JCJose R Castellanos
Jose R Castellanos
IPIan Purvis
Ian Purvis
CLCollin M Labak
Collin M Labak
MGMaheedhara R Guda
Maheedhara R Guda
ATAndrew J Tsung
Andrew J Tsung
SASwapna Asuthkar
Swapna Asuthkar

2 August 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IPIan Purvis
Ian Purvis
JAJanardhan Avilala
Janardhan Avilala
MGMaheedhara Reddy Guda
Maheedhara Reddy Guda
SVSujatha Venkataraman
Sujatha Venkataraman
RVRajeev Vibhakar
Rajeev Vibhakar
SASwapna Asuthkar
Swapna Asuthkar
Medulloblastoma (MB) is the most common embryonal neuroepithelial tumor, with poor patient outcomes and secondary complications. In this study, we investigated the role of the B7 family of immune checkpoint homolog 3 (B7-H3) expression in MB angiogenesis. B7-H3, a co-inhibitory immune checkpoint, is highly expressed and is associated with lower overall survival in MYC+ MB’s. Evidence for a direct transcriptional role of MYC on the B7-H3 gene promoter was confirmed by MYC inhibition and anti-MYC antibody ChIP analysis. Interestingly, MYC inhibition not only downregulated the B7-H3 protein expression, but also rescued miR-29 expression, thus indicating a triangular regulatory relationship between MYC, miR-29, and B7-H3 in Group 3 MB cells. From RNA seq and IPAD assay, we observed a negative feedback loop between miR-29 and MYC that may control B7-H3 expression levels in MB cells. Our studies show that B7-H3 expression levels play a crucial role in promoting MB angiogenesis which can be inhibited by miR-29 overexpression via miR-29-mediated B7-H3 downregulation. The tumor suppressor role of miR-29 is mediated by the activation of JAK/STAT1 signaling that further plays a role in MYC-B7-H3 downregulation in MB. This study highlights B7-H3 as a viable target in MB angiogenesis, and that the expression of miR-29 can inhibit B7-H3 and sensitize MB cells to treatment with MYC-inhibiting drugs.

16 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ATAndrew J. Tsung
Andrew J. Tsung
MGMaheedhara R. Guda
Maheedhara R. Guda
SASwapna Asuthkar
Swapna Asuthkar
CLCollin M. Labak
Collin M. Labak
IPIan Purvis
Ian Purvis
Kiran VelpulaKiran Velpula
Kiran Velpula
Methylation regulates HEY1 expression in glioblastoma Methylation regulates HEY1 expression in glioblastoma

1 March 2017
Verified
Journal Article
Closed access
YLYining Lu
Yining Lu
CLCollin M Labak
Collin M Labak
NJNeha Jain
Neha Jain
IPIan Purvis
Ian Purvis
MGMaheedhara R Guda
Maheedhara R Guda
KVKiran K Velpula
Kiran K Velpula

1 January 2019
Verified
Journal Article
Closed access
WSWade M. Smith
Wade M. Smith
IPIan Purvis
Ian Purvis
CBColin N. Bomstad
Colin N. Bomstad
CLCollin M. Labak
Collin M. Labak
KVKiran K. Velpula
Kiran K. Velpula
SASwapna Asuthkar
Swapna Asuthkar

25 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SASwapna Asuthkar
Swapna Asuthkar
SVSujatha Venkataraman
Sujatha Venkataraman
JAJanardhan Avilala
Janardhan Avilala
KSKatherine Shishido
Katherine Shishido
RVRajeev Vibhakar
Rajeev Vibhakar
Kiran VelpulaKiran Velpula
Kiran Velpula
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Maximum safe resection, postoperative craniospinal irradiation, and chemotherapy are the standard of care for MB patients. MB is classified into four subgroups: Shh, Wnt, Group 3, and Group 4. Of these subgroups, patients with Myc+ Group 3 MB have the worst prognosis, necessitating alternative therapies. There is increasing interest in targeting epigenetic modifiers for treating pediatric cancers, including MB. Using an RNAi functional genomic screen, we identified the lysine methyltransferase SMYD3, as a crucial epigenetic regulator that drives the growth of Group 3 Myc+ MB cells. We demonstrated that SMYD3 directly binds to the cyclin D3 promoter to activate its transcription. Further, SMYD3 depletion significantly reduced MB cell proliferation and led to the downregulation of cyclin D3, cyclin D1, pRBSer795, with concomitant upregulations in RB in vitro. Similar results were obtained following pharmacological inhibition of SMYD3 using BCI-121 ex vivo. SMYD3 knockdown also promoted cyclin D1 ubiquitination, indicating that SMYD3 plays a vital role in stabilizing the cyclin D1 protein. Collectively, our studies demonstrate that SMYD3 drives cell cycle progression in Group 3 Myc+ MB cells and that targeting SMYD3 has the potential to improve clinical outcomes for high-risk patients.